Access to this article is restricted until 12 months after publication by request of the publisher.. Restriction lift date: 2020-02-25
Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes
Loading...
Files
Published Version
Date
2019-02-25
Authors
Roehr, Charles Christoph C.
Banerjee, Rupjani
Alarcon-Allen, Ana
Dempsey, Eugene M.
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley & Sons, Ltd. on behalf of the Cochrane Collaboration
Published Version
Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To review and summarise the existing evidence of the relationship between maternal methylxanthine (including caffeine) consumption (or by any other method of administration) versus no intervention, placebo or a different methylxanthine, before birth with the intention to influence outcomes in preterm newborns, with particular focus on cardiorespiratory adaptation at birth and long-term neurodevelopmental outcomes.
Description
Keywords
Methylxanthine , Caffeine , Cardiorespiratory adaptation , Neurodevelopmental outcomes
Citation
Roehr, C. C. C., Banerjee, R., Alarcon-Allen, A. and Dempsey, E. (2019) 'Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes', Cochrane Database of Systematic Reviews, Issue 2, CD013275 (9pp). doi: 10.1002/14651858.CD013275
Link to publisher’s version
Copyright
© 2019, the Cochrane Collaboration. Published by John Wiley & Sons, Ltd. All rights reserved.